Managers / Q2 2022 · view latest →
HARBOURVEST PARTNERS LLC
CIK 0001201001 · ONE LINCOLN STREET, SUITE 1700, BOSTON, MA, 02111 · 617-348-3707
Reported Value
$305M
Q2 2022
Positions
62
Filings on Record
32
2019–present window
Filed
Aug 15, 2022
original filing
Summary
Harbourvest Partners LLC reported $305M in U.S.-listed holdings across 62 positions for Q2 2022.
Its largest position, W, represents 15.2% of the portfolio.
Compared with Q1 2022, the fund opened 2 new positions and exited 6.
Portfolio Metrics
Turnover
+3.3%
vs prior filed quarter
Top-10 Concentration
+72.9%
share of reported value
Largest Position
+15.2%
Wayfair
New / Exited
2 / 6
positions this quarter
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
13F Reported Value
Portfolio Composition
By security type
- Common Stock · 83.4% · $254M
- Other · 13.7% · $42M
- ADR · 3.0% · $9M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2022 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| HashiCorp, Inc. | NEW | +231.3K | 231.3K | +$7M | $7M |
| WMSAdvanced Drainage Systems, Inc. | NEW | +45.0K | 45.0K | +$4M | $4M |
| KLDOKaleido BioSciences, Inc. | SOLD OUT | −1.83M | 0 | −$3M | $0 |
| Rover Inc. | SOLD OUT | −324.1K | 0 | −$2M | $0 |
| BILLBill.com, Inc. | SOLD OUT | −7.9K | 0 | −$2M | $0 |
| YEXTYext, Inc. | SOLD OUT | −115.1K | 0 | −$793,000 | $0 |
| Root, Inc. | SOLD OUT | −204.3K | 0 | −$402,000 | $0 |
| VCTRVictory Capital Management Inc. | SOLD OUT | −12.0K | 0 | −$346,000 | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2022
62 positions
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | WWayfair Inc.history → | Common CLA | 15.18% | $46M | 1.06M |
| 2 | Solarwinds Corp. | Common | 12.51% | $38M | 3.72M |
| 3 | NABLN-Able, Inc.history → | Common | 10.99% | $33M | 3.72M |
| 4 | TOSTToast, Inc.history → | Common CLA | 9.69% | $30M | 2.28M |
| 5 | AVDXAvidXchange Holdings, Inc.history → | Common | 6.83% | $21M | 3.39M |
| 6 | MNDYmonday.com Ltd.history → | SHS | 6.16% | $19M | 182.0K |
| 7 | Omega Therapeutics, Inc. | Common | 3.30% | $10M | 2.65M |
| 8 | Axcella Health, Inc. | Common | 2.92% | $9M | 4.38M |
| 9 | YMMFull Truck Alliance Co. Ltd.history → | ADR | 2.85% | $9M | 957.6K |
| 10 | Bright Health Group, Inc. | Common | 2.52% | $8M | 4.22M |
| 11 | HashiCorp, Inc. | Common CLA | 2.23% | $7M | 231.3K |
| 12 | Evelo Biosciences, Inc. | Common | 2.12% | $6M | 3.06M |
| 13 | LendingClub Corp. | Common | 1.97% | $6M | 513.4K |
| 14 | RLAYRelay Therapeutics, Inc.history → | Common | 1.63% | $5M | 296.4K |
| 15 | Sonder Holdings, Inc. | Common CLA | 1.54% | $5M | 4.50M |
| 16 | WMSAdvanced Drainage Systems, Inc.history → | Common | 1.33% | $4M | 45.0K |
| 17 | BEBloom Energy Corporationhistory → | Common CLA | 1.20% | $4M | 222.0K |
| 18 | FTCHQFarfetch Ltd.history → | Ordinary Shares CLA | 1.04% | $3M | 442.7K |
| 19 | IASIntegral Ad Science, Inc. | Common | 0.99% | $3M | 305.3K |
| 20 | Squarespace, Inc. | Class A | 0.95% | $3M | 138.8K |
| 21 | Starry Holdings, Inc. | Common CLA | 0.90% | $3M | 666.7K |
| 22 | Inari Medical | Common | 0.86% | $3M | 38.5K |
| 23 | AMPLAmplitude Inc. | Common CLA | 0.72% | $2M | 153.0K |
| 24 | Olo, Inc. | Common CLA | 0.61% | $2M | 188.3K |
| 25 | DOCNDigital Ocean, Inc. | Common | 0.60% | $2M | 44.2K |
| 26 | DOCSDoximity, Inc. | Common CLA | 0.57% | $2M | 49.8K |
| 27 | SPOTSpotify Technology S.A. | SHS | 0.52% | $2M | 16.8K |
| 28 | COURCoursera, Inc. | Common | 0.49% | $2M | 106.1K |
| 29 | Zuora, Inc. | Common | 0.48% | $1M | 163.9K |
| 30 | HNSTThe Honest Company Inc. | Common | 0.46% | $1M | 475.6K |
| 31 | UUnity Software | Common | 0.41% | $1M | 34.2K |
| 32 | IBRXImmunityBio, Inc. | Common | 0.41% | $1M | 335.7K |
| 33 | FROGJfrog Ltd. | ORD SHS | 0.41% | $1M | 59.0K |
| 34 | TWLOTwilio, Inc. | Common CLA | 0.40% | $1M | 14.6K |
| 35 | PATHUiPath, Inc. | Common CLA | 0.38% | $1M | 63.7K |
| 36 | DIBS1stdibs.com, Inc. | Common | 0.37% | $1M | 199.5K |
| 37 | Eventbrite, Inc. | Common CLA | 0.34% | $1M | 102.2K |
| 38 | ONTFON24, Inc. | Common | 0.34% | $1M | 109.2K |
| 39 | ACVAACV Auctions, Inc. | Common CLA | 0.32% | $962,000 | 147.1K |
| 40 | Sumo Logic, Inc. | Common | 0.31% | $957,000 | 127.8K |
| 41 | PGNYProgyny, Inc. | Common | 0.30% | $926,000 | 31.9K |
| 42 | Rubius Therapeutics, Inc. | Common | 0.28% | $840,000 | 986.9K |
| 43 | Sigilon Therapeutics, Inc. | Common | 0.20% | $615,000 | 740.7K |
| 44 | AFRMAffirm, Inc. | Common CLA | 0.14% | $419,000 | 23.2K |
| 45 | HOODRobinhood Markets Inc. | Common CLA | 0.14% | $417,000 | 50.7K |
| 46 | PINSPinterest, Inc. | Common CLA | 0.13% | $387,000 | 21.3K |
| 47 | CPNGCoupang Inc. | Common CLA | 0.11% | $342,000 | 26.8K |
| 48 | Spark Networks SE | Sponsored ADR | 0.11% | $332,000 | 104.2K |
| 49 | FLYWFlywire Corporation | Common Voting | 0.10% | $303,000 | 17.2K |
| 50 | QSQuantumScape Corporation | Common CLA | 0.08% | $249,000 | 29.0K |
| 51 | Astra Space, Inc. | Common CLA | 0.08% | $243,000 | 186.7K |
| 52 | OPENOpendoor Technologies Inc. | Common | 0.07% | $220,000 | 46.7K |
| 53 | Duck Creek Technologies, Inc. | SHS | 0.07% | $215,000 | 14.5K |
| 54 | RPTXRepare Therapeutics, Inc. | Common | 0.06% | $172,000 | 12.3K |
| 55 | Seres Therapeutics, Inc. | Common | 0.06% | $169,000 | 49.4K |
| 56 | PMVPPMV Pharmaceuticals | Common | 0.05% | $164,000 | 11.5K |
| 57 | DASHDoorDash, Inc. | Common CLA | 0.05% | $161,000 | 2.5K |
| 58 | IPSCCentury Therapeutics, Inc. | Common | 0.04% | $123,000 | 14.6K |
| 59 | PACBPacific Biosciences of California, Inc. | Common | 0.03% | $104,000 | 23.5K |
| 60 | OYSTOyster Point Pharma, Inc. | Common | 0.02% | $54,000 | 12.6K |
| 61 | NextCure, Inc. | Common | 0.02% | $47,000 | 10.0K |
| 62 | Aligos Therapeutics, Inc. | Common | 0.01% | $23,000 | 18.8K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $101M | 5 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $174M | 7 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $205M | 9 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $91M | 15 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $154M | 16 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $203M | 22 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $192M | 34 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $188M | 40 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $219M | 48 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $299M | 53 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $295M | 58 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $352M | 60 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $297M | 63 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $299M | 65 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $306M | 67 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $305M | 62 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $490M | 66 | May 26, 2022 | RESTATEMENT | changes · EDGAR ↗ |
| Q4 2021 | $782M | 67 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $1.1B | 56 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $1.0B | 51 | Aug 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $746M | 44 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $256M | 26 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $270M | 36 | Nov 12, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $232M | 28 | Aug 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $207M | 36 | May 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $243M | 35 | Feb 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $240M | 33 | Nov 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $262M | 32 | Aug 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $283M | 33 | May 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $211M | 32 | Feb 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.